Name

Kerecis

Legal name

Kerecis

Website

https://kerecis.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Healing & Dermatologic Regeneration (HLAMANAG)

Keywords

• Fish skin grafts
• Wound care medical devices
• Tissue regeneration products
• Skin substitute grafts
• Burn care biologics

Headquarters

HQ city

Ísafjörður

HQ country

Iceland

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Kerecis generates revenue through the sale of fish-skin based medical devices for wound care, burn treatment, and surgical applications. Products are sold through healthcare providers, hospitals, and authorized distributors. The company operates as a subsidiary of Coloplast following acquisition.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Kerecis develops and manufactures fish-skin based medical devices for wound healing, burn treatment, and surgical applications. The company uses intact fish skin from wild Atlantic cod sustainably sourced from Icelandic waters as a minimally processed, homologous-to-human-skin graft that supports true tissue regeneration. Its product portfolio includes the MariGen line for chronic wounds, Shield for wound care with silicone backing, SurgiClose and SurgiBind for surgical/operating room applications, and GraftGuide for burn management, supplemented by international product lines and a veterinary offering.

Product overview

Kerecis is a medical device company that has developed a proprietary fish-skin technology platform for tissue regeneration and wound healing. The company's products are based on intact fish skin sourced from wild Atlantic cod harvested from sustainable Icelandic fish stocks. The core portfolio includes MariGen (wound care - US), Shield (wound care with silicone backing), SurgiClose/SurgiClose Silicone (surgical applications), SurgiBind (operating room products), and GraftGuide (burn care). These products can be stacked or interspersed in deep wounds to fill deficits and support granulation tissue formation. The fish skin technology is homologous to human skin, provides structural support for cell ingrowth and vascularization, and maintains a natural bacterial barrier. Kerecis also offers veterinary products under the Kerecis VET brand and consumer products under the MariCell line for International/EU markets. The company provides digital services through Kerecis Current. All products are derived from sustainably sourced fish skin, processed using renewable energy with no harsh chemicals, and have a 3-year shelf life with room temperature storage.

Differentiator

Problem solved

Functional benefit

Brands

• MariGen: Fish-skin graft product line for chronic wound management including diabetic foot ulcers, venous leg ulcers, and other hard-to-heal wounds. Available in multiple variations: Solid (intact fish skin), Fenestrated (pre-fenestrated for exudate drainage), Micro (fragmented for deep wound spaces), and Expanse (2:1 pre-meshed for large wounds).
• MariCell
• MariGraft
• MariSurgi
• SurgiClose
• SurgiBind
• Shield
• GraftGuide
• Kerecis VET
• SMOOTH
• FOOTGUARD
• XMA
• PSORIA
• Wunde
• Omega3 Wound

Products and services

• MariGen Intact fish-skin graft product line for wound healing including diabetic foot ulcers, venous leg ulcers, and other chronic wounds. FDA-cleared with labeled intended use for full-thickness wounds with exposed bone and tendon. Available in Solid, Fenestrated, Micro, and Expanse variants.
• Shield Fish-skin graft product with perforated silicone backing that protects the graft while managing exudate and wound moisture. Includes Shield Adhesive variant for outpatient wound care. Covered under CMS skin substitute program.
• SurgiClose Intact fish-skin graft designed for operating room usage, including surgical and trauma wound care applications. SurgiClose Silicone combines intact fish skin with a non-adhesive silicone layer for exudate and moisture management; available in multiple sizes from 3x3 cm to 10x10 cm (bordered and borderless). SurgiClose Micro is fragmented for deep wound spaces.
• SurgiBind Fish-skin graft product for operating room and surgical applications. SurgiBind Tendon Protect is designed to protect and manage newly repaired tendons to minimize scarring and adhesions. Available in fenestrated version for wound management.
• GraftGuide Intact fish-skin graft used for burn wound management to support tissue regeneration and healing. Clinical evidence shows shorter hospital stays for severely burned patients treated with fish-skin grafts compared to synthetic products.
• MariCell Fish-skin product line for International/EU markets for wound care applications, including MariCell Solid for wound care.
• MariGraft Fish-skin graft product for tissue regeneration in International/EU markets.
• MariSurgi Fish-skin surgical product for operating room applications in International/EU markets.
• Kerecis Omega3 Wound Wound care product utilizing omega-3 rich fish skin technology for International/EU markets.
• Wunde Fish-skin wound dressing spray for wound care applications in international markets.
• Kerecis VET Fish-skin graft products specifically designed and available for veterinary/animal health applications, including Kerecis VET Solid for wound closure.
• Kerecis Current Digital services platform aimed at improving patient care with faster digital services.
• MariCell SMOOTH Consumer product line derived from fish skin for personal care applications in international markets.
• MariCell FOOTGUARD Consumer foot care product derived from fish skin technology for international markets.
• MariCell XMA Consumer product derived from fish skin for skin care applications in international markets.
• MariCell PSORIA Consumer product for psoriasis care derived from fish skin technology for international markets.

Quantifiable outcome

• 44% wound healing at 16 weeks vs 26.4% with standard of care for deep DFUs (Odinn RCT)
• +7 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• 3M Health Care / Solventum:
• Mölnlycke Health Care: Mölnlycke is a global wound care and surgical solutions leader (Mepilex, Avance NPWT) with established hospital relationships. It competes with Kerecis in the OR and outpatient wound segments, though Mölnlycke's portfolio does not include fish-skin grafts.
• Coloplast: Coloplast is Kerecis' parent company and one of the largest global wound care and ostomy players. Beyond the corporate relationship, Coloplast's broader wound care portfolio competes with other Kerecis alternatives in the same end markets and channels.
• Smith+Nephew: Smith+Nephew is a large diversified wound care incumbent offering advanced wound dressings, NPWT, and skin substitutes. It competes with Kerecis across hospital and outpatient channels, though it is not focused specifically on fish-skin grafts.
• ConvaTec: ConvaTec is a major wound and ostomy care player with a broad advanced wound care portfolio (including InnovaMatrix placental graft) and competes with Kerecis in the same CMS skin substitute category and wound care specialist channel.
• Integra LifeSciences: Integra LifeSciences markets regenerative tissue technologies (Integra Dermal Regeneration Template, AmnioExcel) for wound and reconstructive surgery, overlapping Kerecis' OR and burn segments. It is a much larger diversified medtech with broader portfolio reach.

Direct peers

• Organogenesis: Organogenesis (ORG) markets Apligraf, Dermagraft, and PuraPly for chronic wound and surgical repair, directly overlapping Kerecis' chronic wound and burn care segments. Both compete for the same hospital outpatient reimbursement and wound clinic formularies.
• MiMedx Group: MiMedx is a direct competitor in the U.S. skin substitute market, selling placental-based grafts (EpiFix, AmnioFix) for chronic wounds including diabetic foot ulcers. Both companies compete for the same CMS-covered skin substitute reimbursement dollars and the same wound care specialist prescriber base.
• MTF Biologics: MTF Biologics provides a range of allograft skin substitutes (AmnioBand, AlloPatch) for chronic wound and surgical applications, competing directly with Kerecis in the same CMS-covered skin substitute category and wound care specialist market.

Emerging players

• Cook Biotech (Cook Medical): Cook Biotech develops and manufactures extracellular matrix grafts (Oasis, Biodesign) for wound care and surgical applications. It is a partial overlap with Kerecis in chronic wound and reconstructive surgery, though with a smaller wound care focus relative to Cook Medical's broader franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/kerecis
• LinkedInlinkedin.com/company/kerecis

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds21 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kerecis